2023年7月12日

加州山景城,2023年7月11日——Smartlens Inc .)、臨床分期眼科技術公司已經關閉了一個超額認購6.1美元的股權融資輪係列為miLens推進監管部門的批準,一部小說,electronics-free,軟性隱形眼鏡監測日眼內壓(IOP)。一輪融資是由範圍健康企業,加入了斯坦福大學,石墨烯,索菲婭創新資本、普萊桑斯資本管理,3 e Bioventures精品Venture Partners和Wilson Sonsini投資與醫生、業內資深人士和關鍵意見領袖。在2023年美國青光眼學會年度會議上,公司對miLens顯示顯著的臨床效果。這個開創性的設備,第一,電子自由軟性隱形眼鏡使用微流體技術。它使監測眼內壓(IOP)以外的青光眼和眼高血壓患者臨床設置。這種發展有潛力改變臨床決策提供以前的數據,允許個性化治療和早期發現青光眼患者。從早期診斷疾病綜合管理,利用這些數據可以幫助防止惡化,同時也為個人提供量身定製的治療青光眼的不同階段。miLens代表一個十年,多學科團隊努力解決一個重要的和未滿足臨床需要。首席執行官薩瓦河Komban Smartlens Inc .)說,“我們很高興與優秀的參與我們的係列,這將帶來miLens一步轉變青光眼護理。我們想感謝我們的合作夥伴的寶貴支持我們的使命。 Understanding the true nature of the disease in each patient throughout the day will allow proactive and well-informed clinical decisions. These decisions will play a vital role in preventing irreversible blindness for millions of glaucoma patients worldwide." Sam Goldberger MD, MBA Co-Founder and Managing Partner of Ambit Health Ventures said, "This technology is of the utmost importance in comprehending glaucoma and the daily fluctuations in intraocular pressure (IOP). Its implementation will enable physicians to enhance glaucoma treatment and mitigate the risk of permanent vision loss. Ambit Health Ventures takes great pride in being involved with this innovative technology." Glaucoma is a group of chronic eye diseases and is the leading cause of irreversible blindness. Elevated IOP is the primary and only treatable risk factor for this condition. According to the World Health Organization (WHO), it is estimated that more than 50% of people with glaucoma are undiagnosed, with over 76 million people suffering from the disease worldwide. This number is expected to increase to 111.8 million by the year 2040. About miLens miLens offers a novel, non-invasive way to monitor IOP in glaucoma and ocular hypertension patients. It has the potential to improve clinical decision-making from diagnosis to the severe stages of the disease by helping to enable personalized treatments, monitoring treatment efficacy, and tracking patient compliance over time to prevent progression and irreversible vision loss. Designed as an electronics-free, soft contact lens, miLens is the smallest wearable microfluidic device available. About Smartlens, Inc. Smartlens, Inc. is an ophthalmic technology company specializing in developing innovative solutions for diagnosing and treating chronic eye diseases. With a strong focus on addressing unmet needs in ophthalmology, the company's pipeline includes cutting-edge technologies that will facilitate improved clinical decision-making while also paving the way for a new generation of therapies. For further information, please visit www.smartlens.health. About Ambit Health Ventures Ambit Health Ventures is a healthcare innovation venture capital firm specializing in early-stage digital health investments. Our leadership team brings a wealth of experience in these sectors, enabling us to drive positive change in the healthcare industry. We are dedicated to improving healthcare by supporting innovative solutions developed by our portfolio companies, all while delivering strong financial returns to our investors. For inquiries, please contact info@smartlens.health